Ligand Pharmaceuticals (FRA:LGDN) Cyclically Adjusted Revenue per Share: €9.43 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
78 GF Score
Price €258.00
GF Value €150.75
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Cyclically Adjusted Revenue per Share?

Ligand Pharmaceuticals FRA:LGDN -1.53% 78 Cyclically Adjusted Revenue per Share is €9.43 as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 78/100 and a GF Value™ of €150.75 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was €2.250. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.43 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ligand Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 11.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 19.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ligand Pharmaceuticals was 24.90% per year. The lowest was -22.90% per year. And the median was 1.90% per year.

As of today (2026-07-16), Ligand Pharmaceuticals's current stock price is €258.00. Ligand Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €9.43. Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 27.36.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ligand Pharmaceuticals was 48.49. The lowest was 5.59. And the median was 14.66.


Ligand Pharmaceuticals  (FRA:LGDN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=258.00/9.43
=27.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ligand Pharmaceuticals was 48.49. The lowest was 5.59. And the median was 14.66.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ligand Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Ligand Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Ligand Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.42 7.69 8.04 9.38 9.36

Ligand Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.30 8.56 8.73 9.36 9.43

FRA:LGDN vs DFTX, CGON, XENE: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


FRA:LGDN
78GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ligand Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.25/330.2130*330.2130
=2.250

Current CPI (Mar. 2026) = 330.2130.

Ligand Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.834 241.018 1.143
201609 0.838 241.428 1.146
201612 1.732 241.432 2.369
201703 1.189 243.801 1.610
201706 1.073 244.955 1.446
201709 1.189 246.819 1.591
201712 1.767 246.524 2.367
201803 1.836 249.554 2.429
201806 3.154 251.989 4.133
201809 1.627 252.439 2.128
201812 2.280 251.233 2.997
201903 1.809 254.202 2.350
201906 1.131 256.143 1.458
201909 1.200 256.759 1.543
201912 1.352 256.974 1.737
202003 1.816 258.115 2.323
202006 2.203 257.797 2.822
202009 2.209 260.280 2.803
202012 2.079 260.474 2.636
202103 2.686 264.877 3.349
202106 4.093 271.696 4.975
202109 3.215 274.310 3.870
202112 1.874 278.802 2.220
202203 1.971 287.504 2.264
202206 2.780 296.311 3.098
202209 3.491 296.808 3.884
202212 2.816 296.797 3.133
202303 2.285 301.836 2.500
202306 1.373 305.109 1.486
202309 1.772 307.789 1.901
202312 1.458 306.746 1.570
202403 1.573 312.332 1.663
202406 2.140 314.175 2.249
202409 2.535 315.301 2.655
202412 2.154 315.605 2.254
202503 2.185 319.799 2.256
202506 2.072 322.561 2.121
202509 4.769 324.800 4.848
202512 2.466 324.054 2.513
202603 2.250 330.213 2.250

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €9.43 mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Cyclically Adjusted Revenue per Share of €9.43 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ligand Pharmaceuticals and its competitors.
Is Ligand Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Ligand Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €9.43. Overall, Ligand Pharmaceuticals has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to DFTX and CGON?
Ligand Pharmaceuticals' Cyclically Adjusted Revenue per Share of €9.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €9.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €150.75, compared to a current price of €258.00 — trading 71.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €9.43. Ligand Pharmaceuticals' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Cyclically Adjusted Revenue per Share is €9.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €258.00 is trading 71.1% above its estimated GF Value™ of €150.75. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Cyclically Adjusted Revenue per Share: €9.43
  • GF Value™: €150.75 vs. price of €258.00 (71.1% above fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
78GF Score

Get the complete analysis for FRA:LGDN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€258.00
Price
€150.75
GF Value